Hall Laurie J Trustee decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 35,161 shares of the company’s stock after selling 113 shares during the quarter. Johnson & Johnson comprises 2.3% of Hall Laurie J Trustee’s holdings, making the stock its 9th largest holding. Hall Laurie J Trustee’s holdings in Johnson & Johnson were worth $5,450,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Glassy Mountain Advisors Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $35,000. GW&K Investment Management LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $35,000. Dark Forest Capital Management LP boosted its position in shares of Johnson & Johnson by 1,044.4% during the fourth quarter. Dark Forest Capital Management LP now owns 206 shares of the company’s stock worth $36,000 after buying an additional 188 shares during the period. Retirement Financial Solutions LLC purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $40,000. Finally, Ruedi Wealth Management Inc. purchased a new position in shares of Johnson & Johnson during the fourth quarter worth $42,000. Institutional investors and hedge funds own 67.57% of the company’s stock.
Analysts Set New Price Targets
Several research firms have recently commented on JNJ. Atlantic Securities lowered their price target on Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Raymond James decreased their target price on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a report on Wednesday, April 19th. UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 target price for the company. Credit Suisse Group lifted their target price on Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. Finally, Guggenheim initiated coverage on Johnson & Johnson in a report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 target price for the company. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $171.57.
Insider Transactions at Johnson & Johnson
Johnson & Johnson Stock Down 0.1 %
JNJ opened at $164.13 on Wednesday. The business’s 50-day simple moving average is $160.72 and its 200-day simple moving average is $163.68. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07. Johnson & Johnson has a one year low of $150.11 and a one year high of $183.35. The stock has a market capitalization of $426.53 billion, a P/E ratio of 34.34, a price-to-earnings-growth ratio of 2.80 and a beta of 0.54.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The business had revenue of $24.75 billion for the quarter, compared to analysts’ expectations of $23.61 billion. During the same quarter in the previous year, the firm earned $2.67 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. Analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Monday, May 22nd. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.13. Johnson & Johnson’s payout ratio is 99.58%.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Read More
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Insider Trading Activity (Form 4 Filings): What is Form 4?
- Innovative Eyewear Stock Surges on Reebok Smart Eyewear Deal
- Is ESG Investing Dead? Fund Outflows Signal Tough Times
- e.l.f. Beauty on a Shelf: Consolidating for the Next Leg Up?
- The Most Upgraded Stocks In Q2
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
